The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Duchenne Muscular Dystrophy
Enrolling by invitation
Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
Is between 7 and 23 years of age, inclusive, at enrollment.
Other inclusion/exclusion criteria apply.
August 5, 2022
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team:
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy NCT03532542